Cargando…
Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149894/ https://www.ncbi.nlm.nih.gov/pubmed/35645314 http://dx.doi.org/10.3390/clinpract12030037 |
_version_ | 1784717302904651776 |
---|---|
author | Pugliese, Maria Elena Battaglia, Riccardo Raso, Maria Girolama Chiaravalloti, Raffaela Coschignano, Francesco Pagliuso, Angela Bruschetta, Roberta Pugliese, Giovanni Scola, Paolo Tonin, Paolo Cerasa, Antonio |
author_facet | Pugliese, Maria Elena Battaglia, Riccardo Raso, Maria Girolama Chiaravalloti, Raffaela Coschignano, Francesco Pagliuso, Angela Bruschetta, Roberta Pugliese, Giovanni Scola, Paolo Tonin, Paolo Cerasa, Antonio |
author_sort | Pugliese, Maria Elena |
collection | PubMed |
description | Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of these patients followed by heterologous booster injection with mRNA-1273 (Moderna). These patients were compared with two different demographically comparable healthcare workers (HCW) groups who underwent homologous booster injection with BNT162b2 vaccine or heterologous booster injection with mRNA-1273. Antibody responses were evaluated at 21 days after the administration of the booster dose of vaccination. Results: No severe adverse reactions were reported after each type of vaccination. Heterologous boosting with mRNA-1273 elicited a higher increase of S-RBD IgG levels than homologous boosting with BNT162b2 both in DOC patients and HCW who had previously received two doses of BNT162b2. No significant difference was detected between DOC and HCW patients who received heterologous boosting. Conclusions: Despite the small sample size, our preliminary results suggest that heterologous boosting with mRNA-1273, following initial vaccination with BNT162b2, is safe and tends to be more immunogenic than homologous boosting, either in fragile people or in healthy controls. |
format | Online Article Text |
id | pubmed-9149894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91498942022-05-31 Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study Pugliese, Maria Elena Battaglia, Riccardo Raso, Maria Girolama Chiaravalloti, Raffaela Coschignano, Francesco Pagliuso, Angela Bruschetta, Roberta Pugliese, Giovanni Scola, Paolo Tonin, Paolo Cerasa, Antonio Clin Pract Communication Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of these patients followed by heterologous booster injection with mRNA-1273 (Moderna). These patients were compared with two different demographically comparable healthcare workers (HCW) groups who underwent homologous booster injection with BNT162b2 vaccine or heterologous booster injection with mRNA-1273. Antibody responses were evaluated at 21 days after the administration of the booster dose of vaccination. Results: No severe adverse reactions were reported after each type of vaccination. Heterologous boosting with mRNA-1273 elicited a higher increase of S-RBD IgG levels than homologous boosting with BNT162b2 both in DOC patients and HCW who had previously received two doses of BNT162b2. No significant difference was detected between DOC and HCW patients who received heterologous boosting. Conclusions: Despite the small sample size, our preliminary results suggest that heterologous boosting with mRNA-1273, following initial vaccination with BNT162b2, is safe and tends to be more immunogenic than homologous boosting, either in fragile people or in healthy controls. MDPI 2022-05-11 /pmc/articles/PMC9149894/ /pubmed/35645314 http://dx.doi.org/10.3390/clinpract12030037 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Pugliese, Maria Elena Battaglia, Riccardo Raso, Maria Girolama Chiaravalloti, Raffaela Coschignano, Francesco Pagliuso, Angela Bruschetta, Roberta Pugliese, Giovanni Scola, Paolo Tonin, Paolo Cerasa, Antonio Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title | Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title_full | Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title_fullStr | Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title_full_unstemmed | Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title_short | Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study |
title_sort | heterologous covid-19 booster vaccination in the chronic disorder of consciousness: a pilot study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149894/ https://www.ncbi.nlm.nih.gov/pubmed/35645314 http://dx.doi.org/10.3390/clinpract12030037 |
work_keys_str_mv | AT pugliesemariaelena heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT battagliariccardo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT rasomariagirolama heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT chiaravallotiraffaela heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT coschignanofrancesco heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT pagliusoangela heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT bruschettaroberta heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT pugliesegiovanni heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT scolapaolo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT toninpaolo heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy AT cerasaantonio heterologouscovid19boostervaccinationinthechronicdisorderofconsciousnessapilotstudy |